ISSUE 93 I APRIL 2020

us excess vs.

global access

While the US battles to control access to opioid pain medication, developing countries are fighting to gain it

Tracking medicine in transit with UPS

What's the deal with Lyme Disease?

Sustainability in pharma

In association with

Tracking medicine in transit with UPS

What's the deal with Lyme Disease?

Sustainability in pharma

02/24/2024 00:22:35
  • Home | US excess vs. global access
  • Editorial
  • VEGA Company Insight
  • VEGA Australia
  • Contents
  • ELPRO Monitoring Solutions
  • News
  • Baxter
  • The pharma industry briefing
  • Datwyler Company Insight
  • Datwyler
  • Turning pharma green: an eco-wish list for the industry
  • Scandinavian Health Company Insight
  • Scandinavian Health
  • Q&A: disrupting DNA synthesis with Twist’s Emily Leproust
  • Phoenix Company Insight
  • Phoenix
  • Tips and tricks for regulating advanced therapies
  • Gerteis Company Insight
  • Gerteis
  • Lyme disease: what's actually going on here?
  • Subcuject Company Insight
  • Subcuject
  • The US and the developing world: a tale of two opioid crises
  • Kugelmeiers
  • Tracking priority medicines in transit: UPS launches tech-enabled service
  • Modality Solutions
  • When deadlines turn deadly: examining the psychology of drug regulators
  • Zenatek
  • Proteus Digital Health: a sharp lesson for smart pills?
  • Mimotopes
  • Deals in brief powered by GlobalData
  • Micronova
  • The key list powered by GlobalData
  • Emisphere
  • Markets and Indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Air France
  • Events
  • ILC Dover
  • Next issue
03/23/2020 00:00:00